The MEYD-773 Expedition
Deep in the heart of the mystical forest of Aethoria, there existed a legend about a place known as MEYD-773. Few spoke of it openly, and even fewer claimed to have seen it. The tales described MEYD-773 not as a thing, but as a gateway—a portal to realms both wondrous and terrifying. The story went that on certain nights, when the moon hung low in the sky and the wind whispered through the trees in a forgotten language, the gateway would appear to those who sought it.
Professor Elara Vex, a renowned archaeologist with a passion for the unexplained and the mystical, had spent her entire career searching for MEYD-773. Her fascination wasn't merely academic; she believed that understanding the gateway could unlock secrets of the universe, secrets that could change the course of human history.
One crisp autumn evening, under the light of a moon that seemed to glow with an ethereal intensity, Elara finally found herself standing before the shimmering portal of MEYD-773. The air around her vibrated with an otherworldly energy, and she could feel the weight of centuries of mystery emanating from the gateway.
With a deep breath, Elara stepped through MEYD-773.
On the other side, she found herself in a realm unlike anything she had ever imagined. The sky was a deep purple, and the ground beneath her feet was made of a material that felt like liquid silver. Strange, luminescent plants towered above her, casting a soft, ethereal glow.
As she explored this new world, Elara encountered beings that defied explanation. They were humanoid in form but possessed abilities that seemed magical. They welcomed her warmly and shared with her the secrets of their world and the nature of MEYD-773.
MEYD-773, Elara learned, was not just a gateway but a nexus—a point of connection between countless worlds and dimensions. It was a place where the fabric of reality was thin, allowing for travel between the vast expanse of the multiverse.
The beings, who called themselves the Guardians of the Nexus, told Elara that she had been chosen to be the ambassador of her world. They presented her with a gift: the knowledge and technology to create a device that could stabilize and navigate the gateway, allowing for safe passage between worlds.
With a heavy heart and a mind buzzing with the implications, Elara returned to her world. She built the device and, over the years, used it to forge alliances with other worlds, bringing about an era of unprecedented peace and advancement.
The legend of MEYD-773 spread, but it was no longer a tale of mystery and fear. It had become a beacon of hope, a reminder of the vastness of the universe and the potential for connection and discovery that lay beyond the boundaries of human understanding.
And Elara, now known as the Ambassador of the Nexus, continued her work, ensuring that the gateway remained a bridge to new possibilities, rather than a barrier to the unknown.
Title:
MEYD‑773: A Novel Small‑Molecule Inhibitor of the PI3K/AKT Pathway with Potent Activity against Triple‑Negative Breast Cancer
Authors:
A. Patel¹, L. Nguyen², M. R. Sanchez³, J. K. Lee¹, S. O. Kim⁴, R. D. Thompson¹*
¹Department of Pharmacology, University of Cambridge, Cambridge, UK
²Institute of Chemical Biology, National University of Singapore, Singapore
³Center for Cancer Research, Universidad Nacional Autónoma de México, Mexico City, Mexico
⁴Division of Oncology, Seoul National University Hospital, Seoul, South Korea
*Correspondence: r.thompson@cam.ac.uk
Orthotopic xenograft: 5 × 10⁶ MDA‑MB‑231 cells (luciferase‑expressing) were injected into the fourth mammary fat pad of 6‑week‑old female athymic nude mice (n = 10/group). Treatment started when tumors reached ~100 mm³: vehicle (0.5 % methylcellulose), MEYD‑773 (20 mg kg⁻¹ p.o. qd), paclitaxel (10 mg kg⁻¹ i.p. weekly), or combination. Tumor volume was measured twice weekly by calipers and bioluminescence imaging.
PDX models: Three TNBC PDXs (BRCA1‑mutated, PTEN‑null, PI3K‑wild‑type) were implanted subcutaneously into NOD/SCID mice (n = 8/group). Dosing regimens mirrored the orthotopic study. Survival was defined as time to tumor volume ≥ 1500 mm³.
Background: Triple‑negative breast cancer (TNBC) lacks expression of estrogen, progesterone, and HER2 receptors, limiting therapeutic options. Hyperactivation of the PI3K/AKT signaling axis is a frequent driver of TNBC progression and resistance to chemotherapy.
Objective: To characterize the pharmacological profile, mechanism of action, and in‑vivo efficacy of MEYD‑773, a newly synthesized heterocyclic scaffold designed to selectively inhibit class I PI3K isoforms.
Methods: A combinatorial library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was screened for PI3K inhibition. MEYD‑773 (chemical name: 6‑[(4‑fluorophenyl)amino]‑2‑(pyridin‑3‑yl)‑1,3‑thiazolo[5,4‑d]pyrimidine) was identified as the lead compound (IC₅₀ = 12 nM for p110α). Kinase selectivity was assessed against a 340‑kinase panel. Cellular activity was evaluated in a panel of breast cancer cell lines (MDA‑MB‑231, HCC‑1806, BT‑549, MCF‑7, and T‑47D). Apoptosis, cell‑cycle distribution, and downstream signaling were examined by flow cytometry, western blot, and phospho‑proteomics. Pharmacokinetics (PK) and tolerability were studied in CD‑1 mice. Antitumor efficacy was tested in orthotopic TNBC xenografts and patient‑derived xenograft (PDX) models.
Results: MEYD‑773 displayed >250‑fold selectivity for class I PI3K over other kinases, with negligible activity against mTOR, DNA‑PK, and CDK families. In vitro, MEYD‑773 reduced p‑AKT (Ser473) and p‑S6 (Ser235/236) levels with EC₅₀ ≈ 30 nM, induced G₁ arrest, and triggered caspase‑3/7‑mediated apoptosis selectively in PI3K‑mutant TNBC cells (IC₅₀ = 0.08‑0.15 µM). PK studies revealed oral bioavailability of 68 %, a half‑life of 7.2 h, and plasma exposure exceeding the in‑vitro EC₅₀ for >12 h at 20 mg kg⁻¹. In orthotopic MDA‑MB‑231 models, daily oral dosing (20 mg kg⁻¹) produced a tumor growth inhibition (TGI) of 82 % (p < 0.001) without weight loss or histopathologic toxicity. In three independent TNBC PDX models (BRCA1‑mutated, PTEN‑null, and wild‑type PI3K), MEYD‑773 achieved TGIs of 71‑89 % and prolonged median survival by 3‑4‑fold compared with vehicle. Combination with standard‑of‑care paclitaxel showed synergistic tumor regression (Combination Index = 0.46).
Conclusions: MEYD‑773 is a highly selective, orally bioavailable PI3K inhibitor with robust preclinical activity against TNBC, including chemoresistant subtypes. These data support advancement of MEYD‑773 into IND‑enabling studies and a first‑in‑human phase I trial in patients with advanced PI3K‑driven TNBC.
Keywords: MEYD‑773, PI3K inhibitor, triple‑negative breast cancer, targeted therapy, preclinical development
MEYD‑773 was a 1.2‑kilometer‑long, torpedo‑shaped leviathan, built from a lattice of graphene‑reinforced carbon‑nanotube composites, capable of withstanding the tidal stresses of the slipstream. Its hull was lined with a thin layer of “phase‑shifted metamaterial” (PSM) that could dynamically adjust its refractive index, allowing the ship to “slide” through the quantum distortion with minimal resistance.
At its heart pulsed the Dual‑Loop Quantum Slipstream Engine (DLQSE), a pair of concentric toroidal reactors that generated and maintained a stable micro‑wormhole. The core used a proprietary blend of hyper‑exotic matter—a form of dark energy stabilized by a lattice of neutrino‑cooled superconductors. The slipstream itself was a 2‑dimensional manifold, a thin sheet of warped spacetime that the ship could enter, traverse, and exit without experiencing the relativistic time dilation that plagued conventional near‑light‑speed travel.
The ship’s interior was divided into three primary zones:
The Bridge & Command Cluster – A semi‑circular command deck that hovered above the central spine of the vessel, offering panoramic holographic views of the slipstream in real time. The bridge was staffed by a cadre of “Slipstream Navigators” who, using a combination of AI‑assisted predictive modeling and bio‑feedback loops, performed the delicate choreography needed to keep the vessel aligned with the quantum conduit.
The Habitat Ring – A rotating torus providing artificial gravity for the crew. It housed living quarters, research labs, hydroponic farms, and a small recreation complex. The ring’s rotation rate was modulated to counteract any residual shear forces from the slipstream, ensuring the crew experienced a stable 1 g environment.
The Cargo Bay – A massive, modular space capable of holding up to 5,000 metric tonnes of freight. The bay could be reconfigured on the fly: refrigerated containers for biological payloads, vacuum‑sealed chambers for delicate nanomaterial, and a special “Zero‑G Stasis Chamber” for items that required protection from both radiation and mechanical stress.
MEYD‑773’s inaugural voyage was slated for 13 April 2153. The mission’s primary objective was to deliver a full load of high‑value cargo from Earth’s orbital hub at Luna‑Base 12 to the newly colonized world of Epsilon Eridani b—a temperate super‑Earth orbiting the third‑closest sun‑like star. The distance, approximately 10.5 light‑years, would normally demand a minimum of 12‑year travel at 0.9c (subject to relativistic time dilation). With the Quantum Slipstream, the transit time could be reduced to four weeks of shipboard time, with only a few days of subjective time passing for the crew, thanks to the near‑instantaneous nature of the slipstream pathway.
Secondary objectives included:
Triple‑negative breast cancer (TNBC) accounts for ~15‑20 % of all breast cancers and is characterized by an aggressive clinical course, early metastasis, and a paucity of targeted therapies (1). Genomic analyses have highlighted the phosphatidylinositol‑3‑kinase (PI3K)/AKT/mTOR axis as a central driver of proliferation, survival, and chemoresistance in TNBC (2,3). While several pan‑class I PI3K inhibitors have entered clinical testing, dose‑limiting toxicities—particularly hyperglycemia, rash, and immune suppression—have limited their therapeutic window (4). Consequently, there is a critical need for next‑generation PI3K inhibitors with improved selectivity, oral bioavailability, and tumor‑specific activity.
Here we report the discovery and preclinical characterization of MEYD‑773, a novel heterocyclic small‑molecule inhibitor derived from a 1,3‑thiazolo[5,4‑d]pyrimidine scaffold. MEYD‑773 was optimized through structure‑activity relationship (SAR) studies to achieve high potency against the p110α catalytic subunit of PI3K, while sparing other class I isoforms (p110β, p110δ, p110γ) and unrelated kinases. We hypothesized that this selectivity would translate into a favorable safety profile and allow sustained inhibition of oncogenic PI3K signaling in TNBC.
The MEYD-773 Expedition
Deep in the heart of the mystical forest of Aethoria, there existed a legend about a place known as MEYD-773. Few spoke of it openly, and even fewer claimed to have seen it. The tales described MEYD-773 not as a thing, but as a gateway—a portal to realms both wondrous and terrifying. The story went that on certain nights, when the moon hung low in the sky and the wind whispered through the trees in a forgotten language, the gateway would appear to those who sought it.
Professor Elara Vex, a renowned archaeologist with a passion for the unexplained and the mystical, had spent her entire career searching for MEYD-773. Her fascination wasn't merely academic; she believed that understanding the gateway could unlock secrets of the universe, secrets that could change the course of human history.
One crisp autumn evening, under the light of a moon that seemed to glow with an ethereal intensity, Elara finally found herself standing before the shimmering portal of MEYD-773. The air around her vibrated with an otherworldly energy, and she could feel the weight of centuries of mystery emanating from the gateway.
With a deep breath, Elara stepped through MEYD-773.
On the other side, she found herself in a realm unlike anything she had ever imagined. The sky was a deep purple, and the ground beneath her feet was made of a material that felt like liquid silver. Strange, luminescent plants towered above her, casting a soft, ethereal glow.
As she explored this new world, Elara encountered beings that defied explanation. They were humanoid in form but possessed abilities that seemed magical. They welcomed her warmly and shared with her the secrets of their world and the nature of MEYD-773.
MEYD-773, Elara learned, was not just a gateway but a nexus—a point of connection between countless worlds and dimensions. It was a place where the fabric of reality was thin, allowing for travel between the vast expanse of the multiverse.
The beings, who called themselves the Guardians of the Nexus, told Elara that she had been chosen to be the ambassador of her world. They presented her with a gift: the knowledge and technology to create a device that could stabilize and navigate the gateway, allowing for safe passage between worlds. MEYD-773
With a heavy heart and a mind buzzing with the implications, Elara returned to her world. She built the device and, over the years, used it to forge alliances with other worlds, bringing about an era of unprecedented peace and advancement.
The legend of MEYD-773 spread, but it was no longer a tale of mystery and fear. It had become a beacon of hope, a reminder of the vastness of the universe and the potential for connection and discovery that lay beyond the boundaries of human understanding.
And Elara, now known as the Ambassador of the Nexus, continued her work, ensuring that the gateway remained a bridge to new possibilities, rather than a barrier to the unknown.
Title:
MEYD‑773: A Novel Small‑Molecule Inhibitor of the PI3K/AKT Pathway with Potent Activity against Triple‑Negative Breast Cancer
Authors:
A. Patel¹, L. Nguyen², M. R. Sanchez³, J. K. Lee¹, S. O. Kim⁴, R. D. Thompson¹*
¹Department of Pharmacology, University of Cambridge, Cambridge, UK
²Institute of Chemical Biology, National University of Singapore, Singapore
³Center for Cancer Research, Universidad Nacional Autónoma de México, Mexico City, Mexico
⁴Division of Oncology, Seoul National University Hospital, Seoul, South Korea
*Correspondence: r.thompson@cam.ac.uk
Orthotopic xenograft: 5 × 10⁶ MDA‑MB‑231 cells (luciferase‑expressing) were injected into the fourth mammary fat pad of 6‑week‑old female athymic nude mice (n = 10/group). Treatment started when tumors reached ~100 mm³: vehicle (0.5 % methylcellulose), MEYD‑773 (20 mg kg⁻¹ p.o. qd), paclitaxel (10 mg kg⁻¹ i.p. weekly), or combination. Tumor volume was measured twice weekly by calipers and bioluminescence imaging. The MEYD-773 Expedition Deep in the heart of
PDX models: Three TNBC PDXs (BRCA1‑mutated, PTEN‑null, PI3K‑wild‑type) were implanted subcutaneously into NOD/SCID mice (n = 8/group). Dosing regimens mirrored the orthotopic study. Survival was defined as time to tumor volume ≥ 1500 mm³.
Background: Triple‑negative breast cancer (TNBC) lacks expression of estrogen, progesterone, and HER2 receptors, limiting therapeutic options. Hyperactivation of the PI3K/AKT signaling axis is a frequent driver of TNBC progression and resistance to chemotherapy.
Objective: To characterize the pharmacological profile, mechanism of action, and in‑vivo efficacy of MEYD‑773, a newly synthesized heterocyclic scaffold designed to selectively inhibit class I PI3K isoforms.
Methods: A combinatorial library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was screened for PI3K inhibition. MEYD‑773 (chemical name: 6‑[(4‑fluorophenyl)amino]‑2‑(pyridin‑3‑yl)‑1,3‑thiazolo[5,4‑d]pyrimidine) was identified as the lead compound (IC₅₀ = 12 nM for p110α). Kinase selectivity was assessed against a 340‑kinase panel. Cellular activity was evaluated in a panel of breast cancer cell lines (MDA‑MB‑231, HCC‑1806, BT‑549, MCF‑7, and T‑47D). Apoptosis, cell‑cycle distribution, and downstream signaling were examined by flow cytometry, western blot, and phospho‑proteomics. Pharmacokinetics (PK) and tolerability were studied in CD‑1 mice. Antitumor efficacy was tested in orthotopic TNBC xenografts and patient‑derived xenograft (PDX) models.
Results: MEYD‑773 displayed >250‑fold selectivity for class I PI3K over other kinases, with negligible activity against mTOR, DNA‑PK, and CDK families. In vitro, MEYD‑773 reduced p‑AKT (Ser473) and p‑S6 (Ser235/236) levels with EC₅₀ ≈ 30 nM, induced G₁ arrest, and triggered caspase‑3/7‑mediated apoptosis selectively in PI3K‑mutant TNBC cells (IC₅₀ = 0.08‑0.15 µM). PK studies revealed oral bioavailability of 68 %, a half‑life of 7.2 h, and plasma exposure exceeding the in‑vitro EC₅₀ for >12 h at 20 mg kg⁻¹. In orthotopic MDA‑MB‑231 models, daily oral dosing (20 mg kg⁻¹) produced a tumor growth inhibition (TGI) of 82 % (p < 0.001) without weight loss or histopathologic toxicity. In three independent TNBC PDX models (BRCA1‑mutated, PTEN‑null, and wild‑type PI3K), MEYD‑773 achieved TGIs of 71‑89 % and prolonged median survival by 3‑4‑fold compared with vehicle. Combination with standard‑of‑care paclitaxel showed synergistic tumor regression (Combination Index = 0.46).
Conclusions: MEYD‑773 is a highly selective, orally bioavailable PI3K inhibitor with robust preclinical activity against TNBC, including chemoresistant subtypes. These data support advancement of MEYD‑773 into IND‑enabling studies and a first‑in‑human phase I trial in patients with advanced PI3K‑driven TNBC.
Keywords: MEYD‑773, PI3K inhibitor, triple‑negative breast cancer, targeted therapy, preclinical development
MEYD‑773 was a 1.2‑kilometer‑long, torpedo‑shaped leviathan, built from a lattice of graphene‑reinforced carbon‑nanotube composites, capable of withstanding the tidal stresses of the slipstream. Its hull was lined with a thin layer of “phase‑shifted metamaterial” (PSM) that could dynamically adjust its refractive index, allowing the ship to “slide” through the quantum distortion with minimal resistance. MEYD‑773: The Long‑Haul Between Stars Chapter 3 –
At its heart pulsed the Dual‑Loop Quantum Slipstream Engine (DLQSE), a pair of concentric toroidal reactors that generated and maintained a stable micro‑wormhole. The core used a proprietary blend of hyper‑exotic matter—a form of dark energy stabilized by a lattice of neutrino‑cooled superconductors. The slipstream itself was a 2‑dimensional manifold, a thin sheet of warped spacetime that the ship could enter, traverse, and exit without experiencing the relativistic time dilation that plagued conventional near‑light‑speed travel.
The ship’s interior was divided into three primary zones:
The Bridge & Command Cluster – A semi‑circular command deck that hovered above the central spine of the vessel, offering panoramic holographic views of the slipstream in real time. The bridge was staffed by a cadre of “Slipstream Navigators” who, using a combination of AI‑assisted predictive modeling and bio‑feedback loops, performed the delicate choreography needed to keep the vessel aligned with the quantum conduit.
The Habitat Ring – A rotating torus providing artificial gravity for the crew. It housed living quarters, research labs, hydroponic farms, and a small recreation complex. The ring’s rotation rate was modulated to counteract any residual shear forces from the slipstream, ensuring the crew experienced a stable 1 g environment.
The Cargo Bay – A massive, modular space capable of holding up to 5,000 metric tonnes of freight. The bay could be reconfigured on the fly: refrigerated containers for biological payloads, vacuum‑sealed chambers for delicate nanomaterial, and a special “Zero‑G Stasis Chamber” for items that required protection from both radiation and mechanical stress.
MEYD‑773’s inaugural voyage was slated for 13 April 2153. The mission’s primary objective was to deliver a full load of high‑value cargo from Earth’s orbital hub at Luna‑Base 12 to the newly colonized world of Epsilon Eridani b—a temperate super‑Earth orbiting the third‑closest sun‑like star. The distance, approximately 10.5 light‑years, would normally demand a minimum of 12‑year travel at 0.9c (subject to relativistic time dilation). With the Quantum Slipstream, the transit time could be reduced to four weeks of shipboard time, with only a few days of subjective time passing for the crew, thanks to the near‑instantaneous nature of the slipstream pathway.
Secondary objectives included:
Triple‑negative breast cancer (TNBC) accounts for ~15‑20 % of all breast cancers and is characterized by an aggressive clinical course, early metastasis, and a paucity of targeted therapies (1). Genomic analyses have highlighted the phosphatidylinositol‑3‑kinase (PI3K)/AKT/mTOR axis as a central driver of proliferation, survival, and chemoresistance in TNBC (2,3). While several pan‑class I PI3K inhibitors have entered clinical testing, dose‑limiting toxicities—particularly hyperglycemia, rash, and immune suppression—have limited their therapeutic window (4). Consequently, there is a critical need for next‑generation PI3K inhibitors with improved selectivity, oral bioavailability, and tumor‑specific activity.
Here we report the discovery and preclinical characterization of MEYD‑773, a novel heterocyclic small‑molecule inhibitor derived from a 1,3‑thiazolo[5,4‑d]pyrimidine scaffold. MEYD‑773 was optimized through structure‑activity relationship (SAR) studies to achieve high potency against the p110α catalytic subunit of PI3K, while sparing other class I isoforms (p110β, p110δ, p110γ) and unrelated kinases. We hypothesized that this selectivity would translate into a favorable safety profile and allow sustained inhibition of oncogenic PI3K signaling in TNBC.
